SCHEMBL23675404

SCHEMBL23675404

O=C(NCC1CCCCC1)c1cc(Cl)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.64
RAB9A P51151 1/20 0.59
CNR2 P34972 2/20 0.57
CNR1 P21554 1/20 0.57
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 1/20 0.56
SENP1 Q9P0U3 1/20 0.56
CDK1 P06493 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
EPHX1 P07099 1/20 0.52
EPHX2 P34913 1/20 0.52
CHRM1 P11229 6/20 0.52
CHRM2 P08172 2/20 0.50
CHRM4 P08173 2/20 0.50
CHRM3 P20309 2/20 0.50
CHRM5 P08912 1/20 0.50
POLB P06746 1/20 0.49
P2RX1 P51575 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26098577 0.86 CDK1 (0.59) NPC1RAB9ACNR2CNR1ALDH1A1
SCHEMBL26098051 0.86 CNR2 (0.53) CNR2CNR1CDK1CHRM1
SCHEMBL27684193 0.85 NPC1 (0.57) NPC1RAB9ACNR2CNR1MEN1
SCHEMBL26098202 0.83 CDK1 (0.49) NPC1CNR2CDK1KMT2ACHRM1
SCHEMBL4345381 0.78 EPHX1 (0.63) NPC1RAB9ACNR2CNR1ALDH1A1
SCHEMBL23675423 0.78 NPC1 (0.63) NPC1RAB9AALDH1A1GAAHPGD
SCHEMBL26096785 0.78 NPC1 (0.63) NPC1RAB9AALDH1A1GAAHPGD
SCHEMBL27684178 0.78 CNR1 (0.72) NPC1RAB9ACNR2CNR1MEN1
SCHEMBL589624 0.77 CHRM1 (0.54) NPC1RAB9ACNR2CNR1CHRM1
SCHEMBL23675376 0.77 KDM4E (0.62) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE NPC1 4093/4885RAB9A 4307/4885CNR2 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.